BRIEF—Enesi Pharma inks deal to create new Shigella vaccine

UK-based vaccine specialist Enesi Pharma has agreed an R&D collaboration with a US Department of Defense research laboratory, regarding Shigella vaccine development.

Enesi, which works on creating injectable solid dose vaccines, will look to create a “robust and stable solid-dose formulation" of the InvaplexAR Shigella vaccine, leveraging its ImplaVax technology.

Chief executive David Hipkiss said: "We have made great progress at Enesi Pharma with the development of our ImplaVax needle-free injection platform since the launch of the company in 2017.”

“In parallel, we have consulted with vaccine manufacturers, emerging companies and research institutes around the world to enhance our understanding of their needs and to discuss and execute a number of potential collaborations.”